Introduction
Edited by: Ritthideach Yorsaeng, Chulalongkorn University, ThailandReviewed by: Asisa Volz, University of Veterinary Medicine Hannover, Germany; Ang Lin, China Pharmaceutical University, China†ORCID: Denis Sauré, This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in ImmunologyBooster doses of SARS-CoV-2 vaccines improve seroconversion rates in solid organ transplant recipients (SOTRs) but the impact of homologous and heterologous booster doses in neutralizing antibody (NAb) titers and their ability to interfere with the variant of concern Omicron are not well studied.